Loading...
XHKG
3320
Market cap3.56bUSD
Jul 09, Last price  
4.44HKD
1D
-1.99%
1Q
-29.97%
Jan 2017
-49.26%
IPO
-50.78%
Name

China Resources Pharmaceutical Group Ltd

Chart & Performance

D1W1MN
XHKG:3320 chart
P/E
6.20
P/S
0.09
EPS
0.72
Div Yield, %
3.04%
Shrs. gr., 5y
Rev. gr., 5y
8.40%
Revenues
300.01b
+9.42%
116,950,696,000135,749,180,000146,568,105,000156,705,203,000172,532,204,000189,689,107,000204,453,869,000200,423,023,000236,806,169,000254,106,366,000270,397,302,000274,182,490,000300,013,084,000
Net income
4.50b
+26.27%
2,639,517,0002,645,940,0002,850,076,0002,821,410,0003,483,036,0004,037,890,0003,286,419,0002,778,656,0003,080,673,0003,500,270,0003,854,247,0003,565,548,0004,502,259,000
CFO
22.78b
+29.91%
4,102,157,0003,347,871,8085,988,790,0004,119,647,0004,857,538,0008,246,965,0005,254,057,0006,277,176,00011,220,436,00010,898,714,00015,549,886,00017,535,514,00022,779,919,000
Dividend
Jun 03, 20260.139 HKD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

China Resources Pharmaceutical Group Limited, an investment holding company, engages in the manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and internationally. It operates through four segments: Pharmaceutical Manufacturing, Pharmaceutical Distribution, Pharmaceutical Retail, and Others. The company offers a range of chemical drugs, Chinese medicines, and biological drugs, as well as nutritional and healthcare products for various therapeutic areas, including cardiovascular and cerebrovascular diseases, alimentary tract, endocrine diseases, respiratory diseases, orthopedics, nephrology, rheumatology and immunology, medical nutrition, pediatrics, genitourinary system, dermatological diseases, blood products, therapeutic infusions, antitumor drugs, medicine for cough and cold, anti-infection drugs, and psychoneurosis. It also provides warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical/medical device manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, the company is involved in property holding activities, as well as operates retail pharmacies under the Teck Soon Hong brands. It distributes its products under the 999, Dong-E-E-Jiao, Double Crane, Zizhu, Jiangzhong, Boya, and Kun Zhong Yao to hospitals and other medical institutions. The company was formerly known as China Resources Medications Group Limited and changed its name to China Resources Pharmaceutical Group Limited in December 2011. The company was incorporated in 2007 and is based in Wan Chai, Hong Kong. China Resources Pharmaceutical Group Limited is a subsidiary of CRH (Pharmaceutical) Limited.
IPO date
Oct 28, 2016
Employees
71,000
Domiciled in
HK
Incorporated in
HK

Valuation

Title
HKD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT